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Leukocyte sequestration and activation is impor-
tant in the pathogenesis of skin changes as the result
of chronic venous disease (CVD). A micronized
purified flavonoid fraction has been used in the
treatment of CVD for a considerable period of time.
The response of leukocyte activation to any form of
therapy in CVD remains unknown.
In 1978 Moyses et al1 reported sequestration of
leukocytes in the circulation of the lower limb after
venous hypertension. CVD and its sequelae are a
major cause of morbidity in the Western world.2
Therefore leukocyte-mediated inflammatory mecha-
nisms have been a focus of attention in CVD. Speiser
and Bollinger3 showed that there were areas of very
low skin blood flow in legs affected with CVD.
These areas diminished on application of compres-
sion stockings. In 1988 Coleridge-Smith et al4 put
forward the hypothesis of leukocyte trapping cause
by the reduction in capillary blood flow because of
an increase in venous pressure. A study published by
the same group in 1997 showed those venous hyper-
tension results in sequestration of the more activat-
ed population of neutrophils and monocytes in the
microcirculation of the leg in patients with CVD.
These cells bind to the endothelium and may not
emerge from the limb when venous hypertension is
reversed.5
The physical interaction between the leukocyte
and the microvascular endothelium is important for
its function in the microvasculature.6 Patients with
chronic inflammatory and septic states show
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Purpose: The purpose of this study was to determine the effects of a micronized purified
flavonoid fraction treatment on surface expression of leukocyte adhesion molecules in
chronic venous disease (CVD).
Methods: Twenty patients with chronic venous disease were assessed with the use of clin-
ical and Duplex scanning criteria. Consenting patients were treated for 60 days with a
micronized purified flavonoid fraction treatment (500 mg twice daily). Blood was col-
lected from a foot vein immediately before the start of treatment and within 1 week after
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sion was determined by flow cytometry using the monoclonal antibodies to CD11b and
CD62L.
Results: Neutrophil CD11b (248:212), monocyte CD11B (204:190), neutrophil
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in the levels of these molecules as a marker for response to therapy in chronic venous dis-
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increased leukocyte priming. This is also observed in
patients with CVD. The primed cells show increased
surface CD62L and CD11B.7 CD62L is involved in
the initial “rolling” movement of the leukocyte
along the endothelium. CD11b is the leukocyte lig-
and responsible for firm adhesion and subsequent
diapedesis. There is some evidence of inflammatory
mechanisms being important in the damage to the
venous valves seen in CVD.8 After any successful
treatment for CVD, a reduction in leukocyte activa-
tion would be expected.
The response of the increased leukocyte activation
in CVD to any form of therapy remains unknown.
Various compounds have been used to treat symptoms
and to reduce complications in CVD. These include
flavonoids (diosmin/hydroxyethyl-rutin), methyl-
xanthines, prostaglandins, and fibrinolytics. No
phlebotonic drug addresses venous valvular
incompetence. However, many of these may affect
the inflammatory changes responsible for the skin
damage and possible vein wall damage in CVD. A
purified micronized flavonoid fraction (Daflon,
500 mg; Servier International France, Paris,
France) has been used in Europe for the treatment
of CVD for some time. This consists of 90%
Diosmin (3´,5,7 trihydroxy-4´-methoxyfiavone 7
rhamnoglucoside; C28 H32 O15) and 10% hes-
peridin flavonoids (3´,5, 7 trihydroxy-4´-methoxy-
flavanone 7 rhamnoglucoside; the micronization
of the effective components may increase its
bioavailability. It has been reported to be a veno-
tonic and to decrease microvascular leakage. A
double-blind randomized trial published in 1994
had shown its efficacy in the treatment of the clin-
ical symptoms of CVD without any significant side
effects. Several pharmacologic properties have
been ascribed to this compound, including
increased venous tone, decreased permeability of
the microvasculature, change in the composition
of the venous wall,9 and increased lymphatic
flow.10 A recent trial showed increased venous
ulcer healing rate in the short term with purified
flavonoid fraction.11
Mainly because of a lack of good controlled tri-
als, the use of pharmacologic treatment is variable,
and there are no clear guidelines for their use in
CVD. It would be logical to think that compounds
that have been claimed to ameliorate CVD should
dampen the increased leukocyte activation in this
condition. The aim of our study was to observe the
effects of 60 days of micronized purified flavonoid
fraction treatment on the expression of leukocyte
adhesion molecules in CVD.
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MATERIAL AND METHODS
Evaluation. Consent for the study was obtained
from the University College London Medical
School Committee for Medical Ethics. Clinical com-
ponents of the CEAP (clinical, etiologic, anatomic,
pathologic) classification were used to stratify
patients.12 Patients with CVD (clinical stage 2
through 4) were recruited from the vascular clinic at
the Middlesex Hospital. These patients were given a
full clinical examination by a surgeon experienced in
the management of patients with CVD. A medical
history was taken, and a clinical examination, which
included a systemic and venous examination, was
performed. All patients underwent full blood count,
serum urea, and electrolyte/liver function tests.
All patients underwent a venous duplex scanning
examination during the previous 8 weeks to establish
venous reflux and to localize the reflux anatomically.
All the deep and superficial veins in the lower limbs
were examined. Venous reflux greater than 0.5 sec-
onds was considered significant.
Patients who consented were asked to return on
three separate occasions. Daflon (500 mg twice
daily) was administered for 60 days (at 2 weeks
before the treatment, the day of the start of the
treatment, and after the treatment was stopped). All
patients wore class II support stockings (exerting
compression at the ankle level of 20-30 mm Hg)
and continued to do so during the study.
Patient selection. The inclusion criteria for the
study were (1) age more than 18 years, (2) Hawaii
stage C2 to C4, (3) C6 with a healed ulcer for at least
4 weeks, and (4) psychologic stability and motivation.
Exclusion criteria for the study were (1) a his-
tory of alcohol or drug abuse; (2) a known history
of allergy or intolerance to diosmin or any other
venotonic agent; (3) active venous ulceration; (4)
diabetes mellitus; (5) impaired hepatic function
(alanine aminotransferase or aspartate aminotrans-
ferase three-fold above the normal limit) or
impaired renal function (serum creatinine, >120
µmol/L); (6) any concomitant debilitating active
disease or abnormality in laboratory test (judged as
clinically significant by the investigator); (7) treat-
ment with other vasoactive drugs within the 15
days before inclusion, (8) an acute/chronic inflam-
matory or infectious disease; (9) deep venous
thrombosis within the past 12 months; (10) super-
ficial venous thrombosis within 3 weeks; (11) use
of steroids, nonsteroidal anti-inflammatory drugs,
other vasoactive drugs, vitamins A, C, and E, or
anticoagulants; (12) previous poor compliance
with treatment; (13) participation in a clinical trial
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within past 3 months; and (14) pregnancy, breast-
feeding, or lack of active contraception.
There were an equal number of patients with and
without skin changes (n = 10 patients) (Table I).
Seven patients in each group had superficial venous
insufficiency (SVI) only. Of the remaining six
patients, most patients (n = 5 patients) had com-
bined SVI and deep venous insufficiency (DVI).
Most patients either had long saphenous vein (LSV)
involvement (n = 9 patients) or combined LSV and
short saphenous vein (SSV) involvement (n = 7
patients). Two patients had CVD that involved nei-
ther of the two major superficial anatomic systems
directly but that involved their tributaries.
Collection of specimens. An 18G cannula
(Vasculon 2; Viggo-Spectramed, Helsingborg,
Sweden) was placed in the distal LSV or dorsal foot
vein of the affected leg. The cannula was flushed
with heparinized saline solution. The patient then
stood supported against the side of the couch for 30
minutes without moving the calf muscles (previous-
ly shown by the authors by direct pressure measure-
ment to raise the venous pressure at the ankle to 70-
80 mm Hg). Two milliliters of blood was taken and
discarded from the cannula, and a further 10 mL of
blood was collected into two tubes that contained
ethylenediaminetetraacetic acid and citrate
(Vacutainer; Becton Dickinson Vacutainer Systems
Europe, Meylan, France) respectively. The stoppers
were removed before blood was added to prevent
excessive cell agitation.
Flow analysis of specimens. Neutrophil and
monocyte CD62L and CD11B were measured within
2 hours of collection. Five microliters of FMLP (1µL
stock + 1049 µL of phosphate-buffered saline solu-
tion) was added to one half of every sample and left at
37°C for 10 minutes. Staining was performed after the
leukocytes had been activated by FMLP. Five micro-
liters of monoclonal antibody (CD11B/CD62L;
R&D Systems Europe, Oxon, UK) was added.
Specimens were further incubated for 30 minutes on
ice. Red blood cells were then lysed (Q-Prep) to
diminish interference during cytometry. Three hun-
dred microliters of solution A (60 µL Formic acid in
50 mL water) was added. Red cells were lysed for 10
seconds. Solution B (carbonated buffer) 132.5 µL was
added for 10 seconds to allow a check of the lysis
process. Fifty microliters of 1% paraformaldehyde
(solution C) was finally added to stabilize the solution.
A flow cytometer (Coulter Epics XL-MCL;
Coulter Electronics Ltd, Luton, UK) was used for
the analysis. Neutrophil and monocyte were gated
with the use of forward- and right-angle scatter.
Fluorescent signals were collected at 525 µm for
CD11b and at 575 µm for CD62L. A minimum of
5000 monocyte events and 10,000 neutrophil
events were collected. Data were analyzed as one
parameter histogram from which mean cell fluores-
cence was obtained. Fluorescent contribution of
aggregates was excluded by integral/height analysis.
These parameters were assessed before and after the
treatment. The levels of statistical significance were
obtained with the use of the Wilcoxon matched-
pairs signed-ranks test.
Patients were asked to complete Visual Analogue
Scoring sheets for symptoms of pain, paresthesia,
Table I. Distribution of the patients according to their CEAP stage and the anatomic location of CVD
SVI DVI SVI/DVI LSV SSV LSV/SSV Other
C2 3 - - 2 1 1 1
C3 4 - 3 2 - 2 1
C4 7 1 2 5 - 4 -
Median age, 58 y 14(2:12) 1(M) 5(3:2) 9(3:6) 1(F) 7(3:4) 2(F)
(range, 39-82 y) (M:F)
Table II. Comparison of changes in mean cell surface fluorescence for CD11B and CD62L before and
after oral flavonoid therapy in 20 patients with simple CVD (C2/C3) and in those patients with dermato-
logic changes (C4)*
N CD11B M CD11B N CD62L M CD62L
C2-3 C4 C2-3 C4 C2-3 C4 C2-3 C4
Before 259 259 194 180 133 130 150 187
After treatment 210 210 128 196 97 110 116 129
P value (Wilcoxon) .03 .05 NS NS <.001 .01 <.001 .01
*The decrease in surface adhesion molecule expression was similar in the two groups in our study.
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edema, cramps, and heaviness before and after treat-
ment. This consisted of a 10-cm line with increasing
severity of symptoms depicted along the line, mov-
ing from the left side (0-10 score). The results were
compared to assess improvement in clinical symp-
toms. The Wilcoxon matched-pairs signed-ranks test
was used to calculate the level of significance.
Differences between the two sets of results from
plasma samples were determined statistically. The
compliance with taking the drug and any adverse
effects were also taken into account.
RESULTS
We found a measurable effect on leukocyte adhe-
sion molecule expression after oral treatment with
Daflon for 60 days. There was a 15% decrease in neu-
trophil CD11B expression (248-212 AU [arbitrary
units of fluorescence]; P = .08). Patients with the
highest levels of CD11B before therapy showed the
greatest decrease. Monocyte CD11B expression was
not significantly affected (204-190 AU); however,
patients with very high initial levels did show a
decrease after treatment. CD62L decreased on both
neutrophils (25% decrease, 130-97 AU; P = .002)
and monocytes. This latter reduction was the highest
in magnitude among the adhesion molecules studied
(29% decrease, 170-121 AU; P = .003; Fig 1, Table
II). The effects of treatment that were seen were sim-
ilar in both groups (C2-3/C4) of patients.
Visual analogue scoring of the symptoms showed
improvement in the subjective parameters of pain,
heaviness, cramps, paresthesia, and edema. Several
patients reported improvement in their venous skin
changes during the treatment although these were
not measured quantitatively. The median compli-
ance rate was 98% (range, 90%-103%). Seven
patients experienced minor side effects (loose
motions, three patients; headache, two patients; and
faintness, 1 patient). All of these patients recovered
spontaneously and preferred to complete the study.
(One patient was lost to follow-up, and another
patient could not continue the study because of an
orthopedic procedure during the course of the
study; both of these patients are not included in the
study).
DISCUSSION
In our study, a micronized purified flavonoid
fraction (Daflon) treatment led to an appreciable
decrease in some leukocyte surface adhesion mole-
cules. The exact medical significance of this amount
of reduction of leukocyte surface molecules is at the
moment unclear. This could block the initial adhe-
sion of these cells to the endothelium and decrease
the amount of tissue damage. Although there have
been studies that showed increased leukocyte activa-
tion in patients with CVD, there are no reports of
the response of this activation to any form of thera-
py. The effect seems to be equivalent in patients with
and without skin changes. (Several patients with skin
changes reported partial resolution of their lipoder-
matosclerosis with 60 days of treatment.) Im-
provement in clinical scores of all the parameters was
seen in the patients treated with purified flavonoid
fraction. This study demonstrates the possibility of
the use of leukocyte activation as a marker for ther-
apy in CVD.
In our study, the number of patients with SVI
and DVI was not equal. One patient had pure DVI;
most patients had SVI only (n = 14 patients) or SVI
as the major element (n = 5 patients). We have pre-
viously shown that no difference in leukocyte activa-
tion exists between patients with SVI or DVI with an
equivalent clinical CEAP stage. The levels of activa-
tion were found to be similar in patients with and
without skin changes and with proven CVD.
Anti-inflammatory actions of flavonoids have
been studied in animal models.13,14 However the
mechanism of action of these compounds in the clin-
ical setting remains unknown. Flavonoids significant-
ly inhibit the macromolecular permeability–increas-
ing effect of histamine, bradykinin, and leukotriene
Fig 1. Changes in neutrophil (N) and monocyte (M) sur-
face fluorescence for adhesion molecules CD62L and
CD11B before and after flavonoid therapy for 60 days (n
= 20 patients). All statistics use the Wilcoxon test. These
results show a decrease in all markers except monocyte
CD11B after therapy. The decrease in CD62L level was
significant statistically. The exact physiologic significance
of this decrease remains to be elucidated.
B4. Flavonoid-treated animals also tend to have a
lower number of leukocytes that adhere to the venu-
lar endothelium.10 Flavonoids have been shown to
decrease the production of free radicals,15 to alter
cytokine release,16 and to have some hemorheologic
effects.17 Some or all of these effects may have clini-
cal relevance. Our study adds to these experimental
studies by providing one explanation for the mecha-
nism of action in the clinical setting of CVD.
Drugs that affect adhesion molecule upregula-
tion may prove important in CVD. Experimental
blockade of adhesion molecules has a dramatic effect
on inflammation and immune-mediated tissue dam-
age.18,19 The effect that any treatment of CVD has
on adhesion molecules has not been studied in the
past. Neutrophil surface adhesion molecule expres-
sion is determined mainly by transport from cyto-
plasmic stores. Decrease in expression of surface
molecules is brought about mainly by protease
cleavage. It is unclear at present as to which of these
stages is affected by flavonoids. Certain anti-inflam-
matory compounds (nonsteroidal anti-inflammatory
drugs) exert their anti-inflammatory effect, at least
in part, through the reduction of neutrophil cell
adhesion molecule expression.20 These effects are
thought to be brought about through enzymatic
cleavage from the cell surface. Protease inhibitors
can block these effects. Purified flavonoid fraction
may have similar effects. The relative lack of side
effects of flavonoids is an important consideration.
Leukocyte sequestration in the microcirculation
of the lower limb is more pronounced in patients
with CVD.1,21 The shear force exerted on leuko-
cytes depends on the velocity of blood flow in the
capillaries.22 It has been shown that, during a venous
hypertensive insult, there is significant fall in leuko-
cyte CD11B and CD62L. On removal of the insult,
there is an increase in the population of CD11B-car-
rying cells, which is suggestive of the release of these
cells from their attachment to the microvascular
endothelium.23 The demonstration of decreased
leukocyte activation in our study could mean possi-
ble beneficial effects in CVD. The role of medical
treatment in increasing the resolution of the skin
changes (eg, after surgical treatment of the varicose
veins) needs to be explored.
This study also supports many findings seen pre-
viously in clinical studies with micronized flavonoid
fraction therapy. A significant decrease in venous
capacitance, venous distensibility, and venous emp-
tying time was shown in a study that involved 183
patients.13 In another study that involved three
groups (different dosage regimens), the mean tran-
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scutaneous oxygen tension significantly increased in
each group, and the mean transcutaneous carbon
dioxide significantly decreased in each group.
However, no significant differences were observed
between the groups on laser Doppler scan parame-
ters.24 The present study shows a measurable effect
of flavonoid treatment a marker of inflammation,
and shows reduced leukocyte activation following
treatment for 60 days.
In conclusion, treatment with purified micronized
flavonoid fraction decreases the surface expression of
CD62L by neutrophils and monocytes in patients
with CVD. These anti-inflammatory effects of puri-
fied micronized flavonoid may be important in their
clinical effects in CVD. It is possible that different
dosages and treatment durations may be needed for
various indications. The role of flavonoids in resolv-
ing skin changes needs to be quantified. It is feasible
to use changes in the level of leukocyte surface adhe-
sion molecules as markers of response to the treat-
ment in CVD. Properly designed double-blind stud-
ies need to be conducted to elucidate these findings.
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